Heshui Wu

6.9k total citations · 1 hit paper
162 papers, 4.7k citations indexed

About

Heshui Wu is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Heshui Wu has authored 162 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 64 papers in Surgery and 53 papers in Molecular Biology. Recurrent topics in Heshui Wu's work include Pancreatic and Hepatic Oncology Research (55 papers), Pancreatitis Pathology and Treatment (36 papers) and Immune Response and Inflammation (15 papers). Heshui Wu is often cited by papers focused on Pancreatic and Hepatic Oncology Research (55 papers), Pancreatitis Pathology and Treatment (36 papers) and Immune Response and Inflammation (15 papers). Heshui Wu collaborates with scholars based in China, United States and Canada. Heshui Wu's co-authors include Chunyou Wang, Xin Jin, Shanmiao Gou, Jiongxin Xiong, Jingyuan Zhao, Zibo Meng, Dianyun Ren, Tao Yin, Yushun Zhang and Tao Peng and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Heshui Wu

155 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic accuracy of the serum lactate level, the SOFA score and the qSOFA score for mortality among adults with Sepsis

2019 213 citations Zibo Meng, Jingyuan Zhao et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heshui Wu China	39	2.2k	1.8k	1.3k	1.0k	812	162	4.7k
Chunyou Wang China	43	2.7k 1.2×	1.7k 0.9×	1.9k 1.5×	893 0.9×	452 0.6×	157	4.9k
Ye Xu China	38	2.9k 1.3×	1.9k 1.1×	2.2k 1.7×	768 0.8×	723 0.9×	187	5.7k
Hushan Yang United States	40	2.8k 1.2×	1.1k 0.6×	2.0k 1.6×	438 0.4×	360 0.4×	124	4.6k
Alessandro Mauriello Italy	38	1.7k 0.8×	547 0.3×	963 0.7×	930 0.9×	1.0k 1.2×	188	5.5k
Hayato Nakagawa Japan	38	2.1k 0.9×	1.4k 0.8×	1.3k 1.0×	1.2k 1.2×	697 0.9×	178	6.1k
Wilfried Renner Austria	36	1.7k 0.8×	774 0.4×	791 0.6×	549 0.5×	501 0.6×	190	4.7k
Shigeki Nakagawa Japan	38	1.7k 0.7×	1.8k 1.0×	994 0.8×	1.2k 1.2×	363 0.4×	184	4.9k
Izumi Takeyoshi Japan	35	1.3k 0.6×	979 0.5×	581 0.4×	1.5k 1.5×	412 0.5×	341	4.4k
Frank Gansauge Germany	33	1.2k 0.6×	1.8k 1.0×	517 0.4×	1.2k 1.2×	326 0.4×	99	3.6k
Hironori Koga Japan	39	1.7k 0.7×	1.0k 0.6×	611 0.5×	762 0.8×	441 0.5×	155	5.3k

Countries citing papers authored by Heshui Wu

Since Specialization

Citations

This map shows the geographic impact of Heshui Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heshui Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heshui Wu more than expected).

Fields of papers citing papers by Heshui Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heshui Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heshui Wu. The network helps show where Heshui Wu may publish in the future.

Co-authorship network of co-authors of Heshui Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Heshui Wu. A scholar is included among the top collaborators of Heshui Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heshui Wu. Heshui Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhao, Yuhan, Xueyi Liang, Haixin Yu, et al.. (2025). BAP1 Represses Sequential Activation of IRAKs and NF-κB Signaling in Pancreatic Cancer. International Journal of Biological Sciences. 21(5). 1949–1965.

Zhou, Aiping, Zheng Li, Yihong Sun, et al.. (2025). LBA84 Efficacy and safety of GFH375 monotherapy in previously treated advanced KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC). Annals of Oncology. 36. S1626–S1626.

Guo, Feng, et al.. (2024). CDK4/6 Alters TBK1 Phosphorylation to Inhibit the STING Signaling Pathway in Prostate Cancer. Cancer Research. 84(16). 2588–2606. 8 indexed citations

Gao, Chuntao, Xingyun Chen, Jihui Hao, et al.. (2024). A randomised phase 2 study of liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxalipalatin versus nab-paclitaxel plus gemcitabine in unresectable locally advanced or metastatic pancreatic cancer.. Journal of Clinical Oncology. 42(16_suppl). 4141–4141.

Wang, Chunyou, Liying Liu, Xin Li, et al.. (2023). Clinical-radiomics nomogram using contrast-enhanced CT to predict histological grade and survival in pancreatic ductal adenocarcinoma. Frontiers in Oncology. 13. 1218128–1218128. 6 indexed citations

Yu, Haixin, Jie Chen, Jian Shen, et al.. (2022). HDAC5 Loss Enhances Phospholipid-Derived Arachidonic Acid Generation and Confers Sensitivity to cPLA2 Inhibition in Pancreatic Cancer. Cancer Research. 82(24). 4542–4554. 13 indexed citations

Zhou, Yingke, Xin Jin, Jian Ma, et al.. (2021). HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer. Cancer Research. 81(6). 1486–1499. 54 indexed citations

Li, Lei, Zhengle Zhang, Yao Guo, et al.. (2021). TRIM47 accelerates aerobic glycolysis and tumor progression through regulating ubiquitination of FBP1 in pancreatic cancer. Pharmacological Research. 166. 105429–105429. 33 indexed citations

Cui, Jing, et al.. (2021). Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling. Molecular Medicine. 27(1). 38–38. 33 indexed citations

10.

Jin, Xin, Yunqian Pan, Liguo Wang, et al.. (2017). Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction. Cancer Research. 77(16). 4328–4341. 77 indexed citations

11.

Peng, Tao, et al.. (2017). Assessment of Red Blood Cell Distribution Width as an Early Predictor of Persistent Organ Failure in Patients with Acute Pancreatitis. JOP, journal of the pancreas. 18(5). 4 indexed citations

12.

Zhang, Yushun, Feng Guo, Zibo Meng, et al.. (2017). Decreased high density lipoprotein cholesterol is an independent predictor for persistent organ failure, pancreatic necrosis and mortality in acute pancreatitis. Scientific Reports. 7(1). 8064–8064. 20 indexed citations

13.

Duan, Qingke, Hengqiang Zhao, Zhengle Zhang, et al.. (2017). Mechanistic Evaluation and Translational Signature of Gemcitabine-induced Chemoresistance by Quantitative Phosphoproteomics Analysis with iTRAQ Labeling Mass Spectrometry. Scientific Reports. 7(1). 12891–12891. 5 indexed citations

14.

Li, Yongfeng, Zhiqiang Liu, Yushun Zhang, et al.. (2016). Implantation of radioactive 125I seeds improves the prognosis of locally advanced pancreatic cancer patients: A retrospective study. Journal of Huazhong University of Science and Technology [Medical Sciences]. 36(2). 205–210. 8 indexed citations

15.

Zhao, Gang, Shanmiao Gou, Jiongxin Xiong, et al.. (2015). Etiology, pathology, management and prognosis of chronic pancreatitis in Chinese population: A retrospective study. Journal of Huazhong University of Science and Technology [Medical Sciences]. 35(3). 384–389. 3 indexed citations

16.

Gou, Shanmiao, Zhiyong Yang, Tao Liu, Heshui Wu, & Chunyou Wang. (2014). Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Critical Care. 18(2). R57–R57. 60 indexed citations

17.

Zhou, Feng, Shanmiao Gou, Jiongxin Xiong, et al.. (2014). Surgical treatment of chronic pancreatitis in young patients. Journal of Huazhong University of Science and Technology [Medical Sciences]. 34(5). 701–705. 1 indexed citations

18.

Yan, Ling, Zhiyong Yang, Tao Yin, et al.. (2010). Heparin changes the conformation of high-mobility group protein 1 and decreases its affinity toward receptor for advanced glycation endproducts in vitro. International Immunopharmacology. 11(2). 187–193. 50 indexed citations

19.

Huang, Peng, et al.. (2008). Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma. World Journal of Gastroenterology. 14(24). 3903–3903. 46 indexed citations

20.

Wang, Hui, Zhuoya Li, Heshui Wu, et al.. (2007). Endogenous danger signals trigger hepatic ischemia/reperfusion injury through toll-like receptor 4/nuclear factor-kappa B pathway. Chinese Medical Journal. 120(6). 509–514. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact